KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Aurinia Pharmaceuticals (AUPH) Receivables - Net (2018 - 2025)

Aurinia Pharmaceuticals' Receivables - Net history spans 7 years, with the latest figure at $41.5 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 13.44% year-over-year to $41.5 million; the TTM value through Dec 2025 reached $41.5 million, up 13.44%, while the annual FY2025 figure was $41.5 million, 13.44% up from the prior year.
  • Receivables - Net reached $41.5 million in Q4 2025 per AUPH's latest filing, up from $30.7 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $41.8 million in Q3 2022 to a low of $1.2 million in Q1 2021.
  • Average Receivables - Net over 5 years is $25.3 million, with a median of $24.8 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: soared 1618.7% in 2022, then decreased 15.77% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $15.4 million in 2021, then fell by 12.42% to $13.5 million in 2022, then surged by 78.44% to $24.1 million in 2023, then skyrocketed by 51.7% to $36.5 million in 2024, then rose by 13.44% to $41.5 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Receivables - Net are $41.5 million (Q4 2025), $30.7 million (Q3 2025), and $40.1 million (Q2 2025).